Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
UTD2 is the world's first oral epothilone microtubule inhibitor
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
Subscribe To Our Newsletter & Stay Updated
